GlassScriptPhysician profile
Christopher Teofil Neagra
NPI 1780034306
$3,357.81
in general payments reported to CMS, 2019-2025
21 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $324 · 2023: $669 · 2024: $1,296 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,032 · Education: $1.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,032.25 |
| Education | $1.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $419.93 | 2022-2025 | Farxiga, Lokelma |
| Amgen INC. | $416.30 | 2023-2025 | Krystexxa, Tavneos |
| Daiichi Sankyo INC. | $396.25 | 2023-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $269.78 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.80 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $193.90 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $183.16 | 2022-2025 | Jynarque |
| Akebia Therapeutics INC | $177.67 | 2023-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $155.77 | 2022-2025 | Filspari |
| Ardelyx, INC. | $146.23 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $131.42 | 2022-2025 | Acthar |
| Vifor Pharma, INC. | $122.37 | 2023-2025 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $100.26 | 2022-2025 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $91.87 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $76.04 | 2023-2024 | Rayaldee |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $73.36 | 2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $57.58 | 2022-2023 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $45.78 | 2024 | |
| Cormedix INC. | $24.15 | 2024 | Defencath |
| Nxstage Medical, INC. | $17.14 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Neagra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.